Metraipolis › archive › dc_54cd70c620db

A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis — Europe PMC PMID:34469480

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/34469480
DOI: 10.1371/journal.pone.0256779
License (as archived): CC0-1.0
Archived: 2026-11-03T02:15:39.305Z
SHA-256 of the archived text: 68792f7604b57bc26964aaa28270fd6dd2a351496e730c436308869696f57d0a
Stable URL of this page: https://metraipolis.com/documento/dc_54cd70c620db

How to cite

A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis — Europe PMC PMID:34469480 — Europe PMC (en), https://europepmc.org/article/MED/34469480 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_54cd70c620db (Metraipolis archive dc_54cd70c620db, sha256 68792f7604b57bc26964aaa28270fd6dd2a351496e730c436308869696f57d0a)

BibTeX

@misc{dc54cd70c620db,
  title = {A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis — Europe PMC PMID:34469480},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34469480},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_54cd70c620db; sha256 68792f7604b57bc26964aaa28270fd6dd2a351496e730c436308869696f57d0a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34469480. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunately, however, RIG is expensive and its supply is limited. Currently, several anti-rabies virus monoclonal antibody (mAb) products are under development as alternatives to RIG, and two recently received regulatory approval in India. In this study, fully human mAbs that recognize different rabies virus glycoprotein conformational antigenic site (II and III) were created from peripheral blood mononuclear cells of heathy vaccinated subjects. These mAbs neutralized a diverse range of lyssavirus types. As at least two anti-rabies virus mAbs are recommended for use in human PEP to ensure broad coverage against diverse lyssaviruses and to minimize possible escape variants, two most potent mAbs, NP-19-9 and 11B6, were selected to be used as cocktail treatment. These two mAbs were broadly reactive to different types of lyssaviruses isolates, and were shown to have no interference with each other. These results suggest that NP-19-9 and 11B6 are potent candidates to be used for PEP, suggesting further studies involving clinical studies in human.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-09-01).
Identificativi: PMID 34469480 · PMCID PMC8409651 · DOI 10.1371/journal.pone.0256779.
Pagina: https://europepmc.org/article/MED/34469480 — https://doi.org/10.1371/journal.pone.0256779. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-03T02:09:31.523Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.